Cargando…

Assessing Blood-Based Biomarkers to Define a Therapeutic Window for Natalizumab

Natalizumab is a monoclonal antibody that binds CD49d. Although it is one of the most effective treatments for Relapsing-Remitting Multiple Sclerosis (RRMS), a dosing regimen has not been optimized for safety and efficacy in individual patients. We aimed to identify biomarkers to monitor Natalizumab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Granell-Geli, Júlia, Izquierdo-Gracia, Cristina, Sellés-Rius, Ares, Teniente-Serra, Aina, Presas-Rodríguez, Silvia, Mansilla, María José, Brieva, Luis, Sotoca, Javier, Mañé-Martínez, María Alba, Moral, Ester, Bragado, Irene, Goelz, Susan, Martínez-Cáceres, Eva, Ramo-Tello, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706232/ https://www.ncbi.nlm.nih.gov/pubmed/34945819 http://dx.doi.org/10.3390/jpm11121347

Ejemplares similares

Optimal response to dimethyl fumarate is mediated by a reduction of Th1‐like Th17 cells after 3 months of treatment
por: Mansilla, María José, et al.
Publicado: (2019)

Th1Th17(CM) Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment
por: Quirant-Sánchez, Bibiana, et al.
Publicado: (2019)

Combined Therapy of Vitamin D3-Tolerogenic Dendritic Cells and Interferon-β in a Preclinical Model of Multiple Sclerosis
por: Quirant-Sánchez, Bibiana, et al.
Publicado: (2021)

MAP7 and MUCL1 Are Biomarkers of Vitamin D3-Induced Tolerogenic Dendritic Cells in Multiple Sclerosis Patients
por: Navarro-Barriuso, Juan, et al.
Publicado: (2019)

Vitamin D3-Induced Tolerogenic Dendritic Cells Modulate the Transcriptomic Profile of T CD4(+) Cells Towards a Functional Hyporesponsiveness
por: Navarro-Barriuso, Juan, et al.
Publicado: (2021)

Transfection of Vitamin D3-Induced Tolerogenic Dendritic Cells for the Silencing of Potential Tolerogenic Genes. Identification of CSF1R-CSF1 Signaling as a Glycolytic Regulator
por: Mansilla, María José, et al.
Publicado: (2021)

Comparative transcriptomic profile of tolerogenic dendritic cells differentiated with vitamin D3, dexamethasone and rapamycin
por: Navarro-Barriuso, Juan, et al.
Publicado: (2018)

Characterization of recent thymic emigrants (RTEs), transitional B and Th17 cells in multiple sclerosis (MS)
por: Teniente-Serra, Aina, et al.
Publicado: (2011)

Epstein-Barr Virus and Multiple Sclerosis: A Convoluted Interaction and the Opportunity to Unravel Predictive Biomarkers
por: Ortega-Hernandez, Oscar-Danilo, et al.
Publicado: (2023)

Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy
por: Mansilla, M. J., et al.
Publicado: (2021)

Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses
por: Ramo-Tello, Cristina, et al.
Publicado: (2021)

Tolerogenic dendritic cells in experimental autoimmune encephalomyelitis, specific tolerance induction?
por: Sellés-Moreno, Carla, et al.
Publicado: (2012)

Cryopreserved vitamin D(3)-tolerogenic dendritic cells pulsed with autoantigens as a potential therapy for multiple sclerosis patients
por: Mansilla, María José, et al.
Publicado: (2016)

Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies
por: Sancho-Saldaña, Agustín, et al.
Publicado: (2022)

SARS-CoV-2: una nueva amenaza
por: López Rodríguez, Cristina A., et al.
Publicado: (2020)

SARS-CoV-2: a new threat
por: López Rodríguez, Cristina A., et al.
Publicado: (2020)

Cytotoxic NK cells phenotype and activated lymphocytes are the main characteristics of patients with alcohol-associated liver disease
por: Zurera-Egea, Coral, et al.
Publicado: (2023)

Personalized Diagnosis and Therapy for Multiple Sclerosis
por: Ramo-Tello, Cristina
Publicado: (2022)

Regulatory role of vitamin D in T-cell reactivity against myelin peptides in relapsing-remitting multiple sclerosis patients
por: Grau-López, Laia, et al.
Publicado: (2012)

Sequencing and Analysis of JC Virus DNA From Natalizumab-Treated PML Patients
por: Reid, Carl E., et al.
Publicado: (2011)

Increased Natural Killer Cells Are Associated with Alcohol Liver Fibrosis and with T Cell and Cytotoxic Subpopulations Change
por: Zuluaga, Paola, et al.
Publicado: (2022)

Identifying Changes in Peripheral Lymphocyte Subpopulations in Adult Onset Type 1 Diabetes
por: Teniente-Serra, Aina, et al.
Publicado: (2021)

Serum levels of IgM to phosphatidylcholine predict the response of multiple sclerosis patients to natalizumab or IFN-β
por: Muñoz, Úrsula, et al.
Publicado: (2022)

Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab
por: Dominguez-Mozo, Maria Inmaculada, et al.
Publicado: (2020)

Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration
por: Willekens, Barbara, et al.
Publicado: (2019)

Natalizumab-induced pneumonitis
por: Kaninia, Stefania, et al.
Publicado: (2021)

Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
por: Lo Buono, Viviana, et al.
Publicado: (2022)

Comparative efficacy of switching to natalizumab in active multiple sclerosis
por: Spelman, Timothy, et al.
Publicado: (2015)

Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study
por: Fernández, O., et al.
Publicado: (2012)

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab
por: Toboso, Inmaculada, et al.
Publicado: (2020)

Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation
por: González‐Suarez, Inés, et al.
Publicado: (2017)

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS
por: Ghezzi, Angelo, et al.
Publicado: (2019)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009)

Natalizumab in the treatment of Crohn’s disease
por: Guagnozzi, Danila, et al.
Publicado: (2008)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

High levels of endothelial ICAM-1 prohibit natalizumab mediated abrogation of CD4(+) T cell arrest on the inflamed BBB under flow in vitro
por: Soldati, Sasha, et al.
Publicado: (2023)

Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
por: Perkins, Molly R., et al.
Publicado: (2012)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_eqn55na4ju5svt4t0tk0tgnu8h